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Abstract
Aims. The Hamilton Depression Rating Scale (HAMD) and the Beck Depression Inventory
(BDI) are the most frequently used observer-rated and self-report scales of depression,
respectively. It is important to know what a given total score or a change score from baseline
on one scale means in relation to the other scale.
Methods. We obtained individual participant data from the randomised controlled trials of
psychological and pharmacological treatments for major depressive disorders. We then iden-
tified corresponding scores of the HAMD and the BDI (369 patients from seven trials) or the
BDI-II (683 patients from another seven trials) using the equipercentile linking method.
Results. The HAMD total scores of 10, 20 and 30 corresponded approximately with the BDI
scores of 10, 27 and 42 or with the BDI-II scores of 13, 32 and 50. The HAMD change scores
of −20 and −10 with the BDI of −29 and −15 and with the BDI-II of −35 and −16.
Conclusions. The results can help clinicians interpret the HAMD or BDI scores of their
patients in a more versatile manner and also help clinicians and researchers evaluate such
scores reported in the literature or the database, when scores on only one of these scales
are provided. We present a conversion table for future research.
Introduction
It is important to evaluate the course of major depressive disorder (MDD) using quantitative
rating scales of symptoms. Various rating scales have been developed to evaluate the severity of
MDD in research and clinical settings. These measures can be categorised as clinician-rated
scales such as the Hamilton Rating Scale for Depression (HAMD) (Hamilton, 1960;
Williams et al., 2008), Montgomery Åsberg Depression Rating Scale (MADRS) (Montgomery
and Asberg, 1979) or Quick Inventory of Depression Symptomatology Clinician Rating (Rush
et al., 2003), and self-report scales such as the Beck Depression Inventory (BDI) (Beck
et al., 1961) and its revised version (BDI-II) (Beck et al., 1996), Patient Health
Questionnaire-9 (Kroenke et al., 2001) or Quick Inventory of Depression Symptomatology
self-report version (Rush et al., 2003). Although numerous scales for rating depression severity
have been developed to date, the HAMD is the most commonly used clinician-rated scale in
research and clinical settings. The HAMD has been used as a main outcome measure in ran-
domised controlled trials of pharmacotherapy and psychotherapy for depression. In the latest
network meta-analysis of antidepressant medications for MDD, 464 of 522 eligible studies
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reported baseline severity scores using the HAMD (Cipriani et al.,
2018). Similarly, the network meta-analysis of psychotherapy for
MDD showed that 75 of 198 studies reported outcomes using the
HAMD (Barth et al., 2013). On the other hand, the BDI is one of
the most widely used self-rating scales. The BDI/BDI-II have been
used particularly often as the outcome measure in psychotherapy
trials. According to the above-mentioned network meta-analysis
studies of psychotherapies for depression, 116 of 198 studies
used the BDI and 25 of 198 studies used the BDI-II as an outcome
measure of the trial (Barth et al., 2013).
Although both the HAMD and the BDI/BDI-II are standard
measures to assess depression severity, no study has yet examined
how scores on the HAMD can be converted to the BDI/BDI-II
scores or vice versa. It is important to link these two most com-
monly used scales for comparison of the baseline severity or treat-
ment outcome. Several studies identified the corresponding scores
of simultaneous HAMD and other scales such as MADRS (Leucht
et al., 2018) and the Clinical Global Impression (Leucht et al.,
2013a) using the equipercentile linking method (Linn, 1993).
The equipercentile linking method has been used extensively for
various other scales in previous publications (Leucht et al.,
2005, 2006, 2013b, 2016; Furukawa et al., 2009; Levine and
Leucht, 2013; Samara et al., 2014). In the current study, we
attempted to link the HAMD and the BDI/BDI-II applying the
same procedure.
Method
Database
We used an existing database of psychological treatments for
depression which is updated annually through comprehensive lit-
erature searches in the bibliographic databases of PubMed,
PsycINFO, EMBASE and the Cochrane Library (Cuijpers et al.,
2008). Appendix A provides the full search strings used. This
database has been used in a series of previously published
meta-analyses (Bower et al., 2013; Furukawa et al., 2017;
Karyotaki et al., 2017). For this linking study, we focused on
the individual participant data (IPD) that we had assembled to
conduct IPD meta-analytic studies comparing cognitive-
behavioural therapy (CBT), antidepressant pharmacotherapy
and their combination (Weitz et al., 2017).
Rating scales
The HAMD is based on clinical interviews. We used the HAMD
17-item version in this analysis. The 17 items consists of nine
symptoms (depressed mood, self-depreciation and guilt feelings,
suicidal impulses, work and interests, psychomotor retardation,
agitation, anxiety psychic, anxiety somatic, hypochondriasis)
rated between 0 (absent) to 4 (very severe), and eight symptoms
(initial insomnia, middle insomnia, delayed insomnia, gastro-
intestinal, general somatic, sexual interests, loss of insight, weight
loss) rated between 0 (absent) to 2 (clearly present) (Hamilton,
1960). The maximum score of the HAMD is therefore 52. A
meta-analysis showed that the HAMD has sufficient internal con-
sistency (Cronbach’s α = 0.79), inter-rater reliability (intra-class
correlation coefficient (ICC) = 0.94) and test–retest reliability
(ICC = 0.93) (Trajkovic et al., 2011).
The BDI is a 21-item patient’s self-report questionnaire that
measures the depression severity (Beck et al., 1961). All items of
the BDI are rated on a four-point Likert scale ranging from 0 to 3,
and the total score therefore ranges from 0 to 63. Beck et al. devel-
oped the revised version of the BDI to harmonise its item con-
tents with the modern diagnostic criteria for MDD in
Diagnostic and Statistical Manual of Mental Disorders
(DSM)-IV, while maintaining the same number of items and
range of scale as the BDI (Beck et al., 1996). The BDI has suffi-
cient internal consistency in psychiatric patients (Cronbach’s α
ranging from 0.76 to 0.95) and non-psychiatric populations
(Cronbach’s α ranging from 0 .73 to 0.92) (Beck et al., 1988).
The BDI-II also has sufficient internal consistency (α = 0.93
among college students, α = 0.92 among outpatients) (Beck
et al., 1996). According to a survey of 1022 undergraduate stu-
dents, the mean score of the BDI-II was 1.54 points higher than
that of the BDI (Dozois et al., 1998). However, the two scales
showed high correlation (r = 0.93), suggesting convergence of
the two scales.
Statistical analysis
We first drew scatterplots and calculated Spearman correlation
coefficients between HAMD and BDI or BDI-II, at baseline and
at end of treatment. We then applied the equipercentile linking
procedure (Linn, 1993), which is a technique that identifies
those scores on the HAMD and the BDI or the BDI-II that
have the same percentile ranks, thus allowing for a nominal trans-
lation from HAMD scores to BDI or BDI-II scores or vice versa
by using their percentile values. We used Microsoft Excel® to real-
ise the analytical procedures described in Chapter 2 of Kolen and
Brennan (1995) and to draw the diagrams. We merged the base-
line and endpoint measurements to produce the final linking
curves and the table of conversion.
Because many trials take the change scores from baseline to
end of treatment, instead of raw scores at end of treatment, as
the primary outcome, we also examined the linking relationships
between change scores of the HAMD and the BDI/BDI-II.
Subgroup and sensitivity analyses
In order to examine possible subgroup differences, we conducted
the same analyses for men and women separately, and also for
dropouts.
Results
Included studies
Figure 1 presents the flow of the literature search. For this study
we used the search that was conducted in January 2016. After
removing the duplicates from different data sources, two inde-
pendent reviewers examined 13 384 titles and abstracts, retrieved
1885 full-text articles and finally identified 75 studies that com-
pared CBT, antidepressant pharmacotherapy or their combination
in the acute phase treatment of depression.
Of these, authors of 14 studies provided IPD including both
HAMD and BDI (Rush et al., 1977; Murphy et al., 1984; Elkin
et al., 1989; Hollon et al., 1992; Jarrett et al., 1999; Reynolds
et al., 1999; Mohr et al., 2001) or BDI-II (DeRubeis et al., 2005;
Dimidjian et al., 2006; Lesperance et al., 2007; McBride et al.,
2007; Dozois et al., 2009; Hegerl et al., 2010; Quilty et al., 2014)
(Table 1). Studies using the BDI were published mainly before
2000, while those using the BDI-II were all published after
2000. The 14 studies included 1536 participants: their mean age
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Fig. 1. Flowchart of study identification.
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Table 1. Included studies and their characteristics
Studies
N Age
Sex (male/
female) Treatments
Treatment duration
(weeks) Scale used for inclusion
Baseline Endpoint
Using BDI HAMD BDI HAMD BDI
Elkin et al. (1989) 116 34.5 35/81 CBT v. ADM 16 HAMD ⩾ 14 19.5 (4.2) 26.7 (8.5) 7.8 (6.8) 9.0 (9.7)
Hollon et al. (1992) 107 32.6 21/86 CBT v. ADM v. CBT + ADM 12 HAMD ⩾ 14 and BDI⩾ 20 23.9 (4.9) 30.7 (7.0) 7.7 (8.2) 9.4 (9.9)
Jarrett et al. (1999) 72 39.3 21/51 CBT v. ADM 10 HAMD ⩾ 14 16.6 (3.1) 25.3 (7.9) 8.1 (6.6) 8.6 (7.8)
Mohr et al. (2001) 45 43.9 9/35 CBT v. ADM 16 HAMD ⩾ 16 and BDI⩾ 16 19.5 (3.8) 20.7 (5.3) 13.4 (6.5) 13.5 (9.5)
Murphy et al. (1984) 33 – 6/27 CBT v. ADM 12 HAMD ⩾ 14 and BDI⩾ 20 18.9 (2.9) 28.9 (6.2) 6.0 (5.1) 8.1 (8.5)
Reynolds et al. (1999) 58 67.3 12/46 IPT v. ADM v. IPT + ADM 16 SADS-L and RDC and
SCID
19.7 (4.1) 17.7 (8.0) 12.4 (4.1) 11.6 (8.1)
Rush et al. (1977) 41 – 15/26 CBT v. ADM 12 HAMD ⩾ 14 and BDI⩾ 20 21.3 (4.0) 30.2 (6.1) 7.3 (5.4) 9.2 (9.8)
All patients with BDI 472 40.5 117/350 20.2 (4.7) 26.2 (8.5) 8.9 (6.9) 9.8 (9.2)
Using BDI-II HAMD BDI-II HAMD BDI-II
DeRubeis et al. (2005) 180 39.9 75/105 CBT v. ADM 16 HAMD ⩾ 20 21.5 (4.0) 32.6 (9.4) 8.3 (6.3) 10.3 (10.4)
Dimidjian et al. (2006) 145 38.9 44/101 CBT v. ADM 16 HAMD ⩾ 14 and BDI-II ⩾
20
18.5 (4.1) 31.9 (7.4) 7.1 (5.6) 9.9 (10.5)
Dozois et al. (2009) 48 45.3 12/36 ADM v. CBT + ADM 15 SCID 18.0 (4.0) 28.6 (9.9) 7.0 (6.6) 12.6 (11.3)
Hegerl et al. (2010) 144 46.7 47/97 CBT v. ADM 10 HAMD ⩾ 8⩽ 22 16.5 (4.3) 21.1 (8.3) 9.0 (6.7) 11.2 (8.3)
Lesperance et al. (2007) 142 57.9 109/33 ADM v. IPT + ADM 12 HAMD ⩾ 20 22.3 (4.9) 30.3 (9.1) 11.7 (7.9) 15.4 (11.1)
McBride et al. (2007) 301 37.4 133/168 CBT v. ADM 24 SCID 19.3 (3.7) 31.9 (9.2) 6.6 (4.9) 11.4 (10.7)
Quilty et al. (2014) 104 33.5 50/54 CBT v. ADM 16 SCID 16.6 (5.1) 29.8 (8.6) 7.9 (6.2) 12.0 (10.8)
All patients with BDI-II 1064 42.0 447/527 19.3 (4.7) 30.4 (9.4) 8.5 (6.5) 12.0 (10.6)
ADM, antidepressant medication; BDI, Beck Depression Inventory; CBT, cognitive-behavioural therapy; HAMD, Hamilton Rating Scale for Depression; IPT, interpersonal psychotherapy; RDC, Research Diagnostic Criteria; SADS-L, Schedule for Affective
Disorders and Schizophrenia-Lifetime Version; SCID, Structured Interview for DSM.
Standard deviations in parentheses.
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was around 40 years, and 61% were women. The treatment lasted
between 10 and 24 weeks, typically for 16 weeks. At baseline, par-
ticipants presented with average HAMD scores around 20, which
dropped to scores around 9 at end of treatment. Seven studies
used the BDI, which dropped from around 26 to around 10;
another seven studies used the BDI-II, which dropped from
around 30 to 12, on average.
Correlations between HAMD and BDI, BDI-II
Figure 2 presents the scatterplots between HAMD and BDI or
BDI-II at baseline and at end of treatment. The correlations
between the HAMD and BDI or BDI-II were relatively weak,
with Spearman correlation coefficients of 0.37 and 0.36, respect-
ively: the raw data were scattered relatively widely, and there
were few data points with a HAMD score of 10 or below, or 30
or higher. At the end of treatment, the correlations between the
HAMD and BDI or BDI-II were stronger (r = 0.73 and 0.74,
respectively), with raw data distributed in a more elliptic manner
predominantly below a HAMD score of 20. When the baseline
observations and end-of-treatment observations were combined,
the correlations between the scales rose to 0.77 and 0.76,
respectively.
There were moderately strong correlations between change
scores: the Spearman correlation coefficients were 0.69 and 0.61
for the HAMD and the BDI or BDI-II change scores, respectively.
Subgroup and sensitivity analyses
Appendix B shows the scatterplots formen andwomen separately at
baseline and at endpoint. Appendix C provides the scatterplots for
those who would later drop out and those who would complete the
studies separately. The equipercentile linkingswere essentially simi-
lar across these subgroups, and hence with the overall findings.
Linking HAMD and BDI, BDI-II
Figure 3 depicts the linking curves between HAMD and BDI or
BDI-II: 3a in terms of raw scores and 3b in terms of change
scores. Table 2 summarises the correspondences on each of
these scales. Outside of the ranges displayed and tabled; there
were too few data for linking.
Discussion
We have obtained IPD from 14 randomised controlled trials of
psychotherapies for the acute phase treatment of depression
Fig. 2. Scatterplots of HAMD and BDI, BDI-II, superimposed with equipercentile linking.
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(total n = 1536 participants), in which the HAMD and the BDI/
BDI-II were administered concurrently both at baseline and at
end of treatment. The equipercentile linking between the HAMD
and the BDI/BDI-II raw scores or change scores established that
the HAMD scores of 10, 20 and 30 corresponded approximately
with the BDI of 10, 27 and 42 or with the BDI-II of 13, 32 and
50; the HAMD change scores of −20 and −10 with the BDI of
−29 and −15 and with the BDI-II of −35 and −16.
It is worthwhile to note that the BDI-II tended to produce
higher scores than the original BDI. This was noted originally
when the BDI-II was first developed (Beck et al., 1996) and repli-
cated subsequently (Dozois et al., 1998), as the BDI-II dropped or
reworded items that poorly reflected depression severity in the
original BDI. Our linking analyses correctly reflected this differ-
ence between the BDI and the BDI-II.
Possible weaknesses of this study include the following. First,
our IPD dataset included only trials that compared psychothera-
pies against pharmacotherapies or their combinations. Some
might suspect that the relationship between the HAMD and the
BDI/BDI-II could be different if the data were derived from
pharmacotherapy trials. Likewise, the datasets were limited to
individuals with major depression who sought treatment. It is
possible that linking results could be different among people in
the community suffering from major depression but not seeking
treatment. However, as this linking study is not about treatments
Fig. 3. Linking curves between HAMD and BDI, BDI-II.
Table 2. Conversion from HAMD to BDI or BDI-II scores
Total scores Change scores
HAMD BDI BDI-II HAMD BDI BDI-II
0 0 0 −5 −7 −6
1 1 1 −4 −5 −5
2 2 2 −3 −4 −4
3 3 3 −2 −2 −2
4 4 5 −1 −1 −1
5 5 6 0 0 0
6 6 8 1 1 2
7 7 9 2 2 3
8 8 11 3 3 5
9 9 12 4 4 6
10 10 13 5 6 7
11 12 15 6 7 9
12 13 16 7 9 11
13 15 18 8 11 12
14 16 20 9 13 14
15 17 21 10 15 16
16 19 23 11 16 18
17 21 25 12 18 20
18 23 27 13 20 22
19 25 30 14 21 23
20 27 32 15 22 25
21 28 34 16 24 27
22 30 36 17 25 29
23 31 38 18 26 31
24 33 40 19 27 33
25 34 42 20 29 35
26 36 44 21 30 36
27 38 45 22 31 38
28 39 47 23 33 39
29 41 49 24 34 41
30 42 50 25 35 43
BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory, 2nd Edition; HAMD,
Hamilton Rating Scale for Depression.
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but about measurements, we do not foresee any strong reason that
there would be major differences. Second, the correlations
between the HAMD and the BDI/BDI-II were only moderate at
baseline. This is reflected by rounder, rather than elliptic, scatter-
plots between the HAMD and the BDI/BDI-II at baseline (Fig. 2).
We originally suspected that there may have arisen some ‘baseline
inflation’ through which people tended to overestimate the
depression severity at baseline when a certain threshold on that
scale was used as a cutoff criterion for eligibility. Focusing on
the four studies that did not use a cutoff (cf Table 1), however,
did not improve the correlation coefficients at baseline. A possi-
bility remains that the observed low correlation at baseline is
due to range restriction of the available scores on HAMD and
BDI/BDI-II as indicated by smaller standard deviations of these
scores at baseline than at endpoint. Another possibility is that par-
ticipants may have been engaging in impression management,
either by overreporting or underreporting their symptoms in
the self-reports, especially at the start of the trial: as the trial pro-
gresses, they may feel less need for such impression management.
Third, it must be pointed out that observer- and self-ratings of
depression severity do not in general show perfect correlations
and that their contrasts can sometimes provide clinically useful
information (Petkova et al., 2000; Targum et al., 2013). The con-
version algorithm as presented in this study must therefore serve
as a rough guide when only one of HAMD/BDI/BDI-II is avail-
able and one wishes to know the approximately equivalent scores.
Last, the linking above the HAMD scores of 30, where there were
few endpoint measurements, may require appropriate caution.
Alternatively it may be safer to convert the change scores rather
than raw scores when researchers would like to use one common
scale across different studies.
On the other hand, the current study also has several major
strengths. This is the first study to empirically link the most rep-
resentative observer-rated instrument and the most frequently
used self-rating instrument for depression, based on data from
over 1500 participants. The conversion table will help clinicians
interpret the HAMD or BDI/BDI-II scores of their patients in a
more versatile manner as they can now convert each scale into
another. Clinicians will also find it easier to compare their
patients’ scores with those reported in the literature when the
latter only reports one of these scales while they have only scores
from the other scales for their patients. The conversion table will
also be informative for researchers when they compare trials
using one but not the other of these scales; in particular, the
table will allow researchers to convert these scales onto the
common scale so that they would need less assumption when
they conduct IPD meta-analysis (Furukawa et al., 2018); without
the conversion the only way to pool individual data was via stand-
ardisation assuming a consistent and common standard deviation
(Bower et al., 2013). For the latter purpose one might prefer to
use the conversion of the change scores as they showed higher
correlations among the scales.
In conclusion, this study provided the first empirically-derived
conversion table between the HAMD and the BDI/BDI-II. The
table is expected to be of help to both clinicians and researchers.
Data and materials. Data used in this study are not available for sharing due
to ethical and data management requirements. The researchers are open to
collaboration.
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Appendix
Translating the BDI and BDI-II into the HAMD and vice versa with equiper-
centile linking
Appendix A. Search string for PubMed
(Psychotherapy [MH] OR psychotherap*[All Fields] OR cbt[All Fields] OR
“behavior therapies”[All Fields] OR “behavior therapy”[All Fields] OR “behav-
ior therapeutic”[All Fields] OR “behavior therapeutical”[All Fields] OR
“behavior therapeutics”[All Fields] OR “behavior therapeutist”[all Fields] OR
“behavior therapeutists”[All Fields] OR “behavior treatment”[All Fields] OR
“behavior treatments”[All Fields] OR “behaviors therapies”[All Fields] OR
“behaviors therapy”[All Fields] OR “behaviors therapeutics”[All Fields] OR
“behaviors therapeutic”[All Fields] OR “behaviors therapeutical”[All Fields]
OR “behaviors therapeutist”[All Fields] OR “behaviors therapeutists”[All
Fields] OR “behaviors treatment”[All Fields] OR “behaviors treatments”[All
Fields] OR “behavioral therapies”[All Fields] OR “behavioral therapy”[All
Fields] OR “behavioral therapeutics”[All Fields] OR “behavioral
therapeutic”[All Fields] OR “behavioral therapeutical”[All Fields] OR “behav-
ioral therapeutist”[All Fields] OR “behavioral therapeutists”[All Fields] OR
“behavioral treatment”[All Fields] OR “behavioral treatments”[All Fields]
OR “behaviour therapies”[All Fields] OR “behaviour therapy”[All Fields] OR
“behaviour therapeutic”[All Fields] OR “behaviour therapeutical”[All Fields]
OR “behaviour therapeutics”[All Fields] OR “behaviour therapeutist”[all
Fields] OR “behaviour therapeutists”[All Fields] OR “behaviour
treatment”[All Fields] OR “behaviour treatments”[All Fields] OR “behaviours
therapies”[All Fields] OR “behaviours therapy”[All Fields] OR “behaviours
therapeutics”[All Fields] OR “behaviours therapeutic”[All Fields] OR “beha-
viours therapeutical”[All Fields] OR “behaviours therapeutist”[All Fields] OR
“behaviours therapeutists”[All Fields] OR “behaviours treatment”[All Fields]
OR “behaviours treatments”[All Fields] OR “behavioural therapies”
[All Fields] OR “behavioural therapy”[All Fields] OR “behavioural
therapeutics”[All Fields] OR “behavioural therapeutic”[All Fields] OR “behav-
ioural therapeutical”[All Fields] OR “behavioural therapeutist”[All Fields] OR
“behavioural therapeutists”[All Fields] OR “behavioural treatment”[All Fields]
OR “behavioural treatments”[All Fields] OR “cognition therapies”[All Fields]
OR “cognition therapie”[All Fields] OR “cognition therapy”[All Fields] OR
“cognition therapeutical”[All Fields] OR “cognition therapeutic”[All Fields]
OR “cognition therapeutics”[All Fields] OR “cognition therapeutist”[All
Fields] OR “cognition therapeutists”[All Fields] OR “cognition
treatment”[All Fields] OR “cognition treatments”[All Fields] OR psycho-
dynamic[All Fields] OR Psychoanalysis[MH] OR psychoanalysis[All Fields]
OR psychoanalytic*[All Fields] OR counselling[All Fields] OR counseling
[All Fields] OR Counseling[MH] OR “problem-solving”[All Fields] OR mind-
fulness[All Fields] OR (acceptance[All Fields] AND commitment[All Fields])
OR “assertiveness training”[All Fields] OR “behavior activation”[All Fields]
OR “behaviors activation”[All Fields] OR “behavioral activation”[All Fields]
OR “cognitive therapies”[All Fields] OR “cognitive therapy”[All Fields] OR
“cognitive therapeutic”[All Fields] OR “cognitive therapeutics”[All Fields]
OR “cognitive therapeutical”[All Fields] OR “cognitive therapeutist”[All
Fields] OR “cognitive therapeutists”[All Fields] OR “cognitive treatment”[All
Fields] OR “cognitive treatments”[All Fields] OR “cognitive restructuring”[All
Fields] OR ((“compassion-focused”[All Fields] OR “compassion-focussed”[All
Fields]) AND (therapy[SH] OR therapies[All Fields] OR therapy[All Fields]
OR therape*[All Fields] OR therapis*[All Fields]OR Therapeutics [OR treat-
ment*[All Fields])) OR ((therapy[SH] OR therapies[All Fields]
OR therapy [All Fields] OR therape*[All Fields] OR therapis*[All Fields]
OR Therapeutics[MH] OR treatment*[All Fields]) AND constructivist*[All
Fields]) OR “metacognitive therapies”[All Fields] OR “metacognitive
therapy”[All Fields] OR “metacognitive therapeutic”[All Fields] OR “metacog-
nitive therapeutics”[All Fields] OR “metacognitive therapeutical”[All Fields]
OR “metacognitive therapeutist”[All Fields] OR “metacognitive
therapeutists”[All Fields] OR “metacognitive treatment”[All Fields] OR “meta-
cognitive treatments”[All Fields] OR “meta-cognitive therapies”[All Fields] OR
“meta-cognitive therapy”[All Fields] OR “meta-cognitive therapeutic”[All
Fields] OR “meta-cognitive therapeutics”[All Fields] OR “meta-cognitive
therapeutical”[All Fields] OR “meta-cognitive therapeutist”[All Fields] OR
“meta-cognitive therapeutists”[All Fields] OR “meta-cognitive treatment”[All
Fields] OR “meta-cognitive treatments”[All Fields] OR “solution-focused
therapies”[All Fields] OR “solution-focused therapy”[All Fields] OR “solution-
focused therapeutic”[All Fields] OR “solution-focused therapeutics”
[All Fields] OR “solution-focused therapeutical”[All Fields] OR “solution
focused therapies”[All Fields] OR “solution focused therapy”[All Fields] OR
“solution focused therapeutic”[All Fields] OR “solution focused
therapeutics”[All Fields] OR “solution focused therapeutical”[All Fields]OR
“solution-focussed therapies”[All Fields] OR “solution-focussed therapy”[All
Fields] OR “solution-focussed therapeutic”[All Fields] OR “solution-focussed
therapeutics”[All Fields] OR “solution-focussed therapeutical”[All Fields]OR
“solution focussed therapies”[All Fields] OR “solution focussed therapy”[All
Fields] OR “solution focussed therapeutic”[All Fields] OR “solution focussed
therapeutics”[All Fields] OR “solution focussed therapeutical”[All Fields] OR
“self-control therapies”[All Fields] OR “self-control therapy”[All Fields] OR
“self-control therapeutics”[All Fields] OR “self-control therapeutical”[All
Fields] OR “self-control therapeutic”[All Fields] OR “self-control
training”[All Fields] OR “self-control trainings”[All Fields] OR “self control
therapies”[All Fields] OR “self control therapy”[All Fields] OR “self control
therapeutics”[All Fields] OR “self control therapeutical”[All Fields] OR “self
control therapeutic”[All Fields] OR “self control training”[All Fields] OR
“self control trainings”[All Fields] AND (Depressive Disorder[MH] OR
Depression[MH]OR dysthymi*[All Fields] OR “affective disorder”[All
Fields]OR “affective disorders”[All Fields] OR “mood disorder”[All Fields]
OR “mood disorders”[All Fields] OR depression*[All Fields] OR depressive*
[All Fields] OR “dysthymic disorder”[MeSH Terms]) AND ((randomized con-
trolled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR
randomly [tiab] NOT (animals[mh] NOT (animals[mh] AND humans [mh]))
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Appendix B. Subgroup analyses by sex
B1. Men
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Appendix C. Subgroup analyses by completers and
dropouts
C1. Dropouts
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